Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Endovia Health Sciences, Inc.SBEV · Entity 8508 | Interim CFO | June 08, 2026 | June 10, 2026 |
| Luvu Brands, Inc.LUVU · Entity 8492 | Chief Financial Officer | September 01, 2023 | September 06, 2023 |
| MGO Global Inc.MGOL · Entity 84273 | CHIEF FINANCIAL OFFICER | January 12, 2023 | January 19, 2023 |
| ShiftPixy, Inc.PIXY · Entity 87121 | Director | January 16, 2024 | January 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Endovia Health Sciences, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2036-06-08 | Direct | 700,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 700,000 · Balance 700,000 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested.
Luvu Brands, Inc.
Report date September 01, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.08 | Direct | 200,000 |
Reported balance
After 2023-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-01 · Grant · Acquired 200,000 · Balance 200,000 F1: The incentive stock options were issued pursuant to the Issuer's 2015 Equity Incentive Plan. The incentive stock options vest and are exercisable at 50% per year, the initial 50% one year from the Transaction Date unless otherwise accelerated, subject to continued employment with the Company on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The incentive stock options were issued pursuant to the Issuer's 2015 Equity Incentive Plan. The incentive stock options vest and are exercisable at 50% per year, the initial 50% one year from the Transaction Date unless otherwise accelerated, subject to continued employment with the Company on each applicable vesting date.
MGO Global Inc.
Report date January 12, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-01-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Issuer granted Mr. Scott 40,000 restricted stock units ("RSU") that will vest on January 13, 2024 with each RSU becoming 1 shares of common stock of the Issuer. F2: N/A |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer granted Mr. Scott 40,000 restricted stock units ("RSU") that will vest on January 13, 2024 with each RSU becoming 1 shares of common stock of the Issuer.
F2: N/A
ShiftPixy, Inc.
Report date January 16, 2024 · Filed January 23, 2024
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 20:31 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantStock Options (Right to Buy) · Derivative | 700,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001731122-26-000832 · ownership.xml · derivative · entry 1 Scott Martin P · CIK 0001306996 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2036-06-08 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested. F1 · price: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options are fully vested. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 19:58 UTC | Luvu Brands, Inc. LUVU · Entity 8492 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001654954-23-011605 · section16.xml · derivative · entry 1 Scott Martin P · CIK 0001306996 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: The incentive stock options were issued pursuant to the Issuer's 2015 Equity Incentive Plan. The incentive stock options vest and are exercisable at 50% per year, the initial 50% one year from the Transaction Date unless otherwise accelerated, subject to continued employment with the Company on each applicable vesting date. F1 · derivative.expiration_date: The incentive stock options were issued pursuant to the Issuer's 2015 Equity Incentive Plan. The incentive stock options vest and are exercisable at 50% per year, the initial 50% one year from the Transaction Date unless otherwise accelerated, subject to continued employment with the Company on each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.